<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003427</url>
  </required_header>
  <id_info>
    <org_study_id>PekingUMCH-OralFAP</org_study_id>
    <nct_id>NCT05003427</nct_id>
  </id_info>
  <brief_title>68Ga-FAPI-04 PET/CT for the Detection of Oral Carcinoma</brief_title>
  <official_title>68Ga-FAPI-04 PET/CT for the Detection of Oral Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FAPI is a fibroblast activation protein inhibitor and 68Ga-FAPI-04 is a potential new imaging&#xD;
      agent for imaging of carcinoma. 68Ga-FAPI-04 PET/CT is helpful to clarify the benign,&#xD;
      malignant and invasive range of the oral carcinoma, locate and qualitatively diagnose the&#xD;
      tumor, and make early diagnosis and restaging of recurrent tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sometimes, the traditional 18F-FDG PET/CT diagnosis of head and neck tumors mistakenly&#xD;
      diagnosed inflammatory lymph nodes as metastatic lymph nodes, resulting in false positive&#xD;
      results. Fibroblast activation protein (FAP) is a serine peptidase on the surface of tumor&#xD;
      associated fibroblasts. It plays an important role in promoting the growth, invasion,&#xD;
      metastasis and immunosuppression of tumor cells. FAPI is a fibroblast activation protein&#xD;
      inhibitor and 68Ga-FAPI-04 is a potential new imaging agent for imaging of carcinoma.&#xD;
      68Ga-FAPI-04 PET/CT is helpful to clarify the benign, malignant and invasive range of the&#xD;
      oral carcinoma, locate and qualitatively diagnose the tumor, and make early diagnosis and&#xD;
      restaging of recurrent tumor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake value of 68Ga-FAPI-04 in oral carcinoma</measure>
    <time_frame>1 year</time_frame>
    <description>The quantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (SUV) of the tracer in oral carcinoma will be measured. The main findings will be compared with other imaging examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>1 week</time_frame>
    <description>Adverse events within 1 week after the injection and scanning of patients and patients will be followed and assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Oral Carcinoma</condition>
  <arm_group>
    <arm_group_label>68Ga-FAPI-04 PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients were injected with 55.5-148 MBq (1.5-4mCi) of 68Ga-FAPI-04 in one dose intravenously and underwent SPECT/CT scan 30-90 min later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-FAPI-04</intervention_name>
    <description>68Ga-FAPI-04 were injected into the patients before the PET/CT scans</description>
    <arm_group_label>68Ga-FAPI-04 PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients in suspicion of oral carcinoma,and being able to provide basic information&#xD;
             and sign the written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or&#xD;
             liver failure, inability to fulfill the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rongxi Wang</last_name>
    <phone>+8619800370331</phone>
    <email>pumch_jacobwong@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhaohui Zhu, MD</last_name>
    <phone>13611093752</phone>
    <email>13611093752@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rongxi Wang</last_name>
      <phone>+8619800370331</phone>
      <email>pumch_jacobwong@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>FAPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lip Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

